IBDEI0PQ ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11565,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11565,1,3,0)
 ;;=3^Secondary Hyperparathyroidism of Renal Origin
 ;;^UTILITY(U,$J,358.3,11565,1,4,0)
 ;;=4^N25.81
 ;;^UTILITY(U,$J,358.3,11565,2)
 ;;=^5015617
 ;;^UTILITY(U,$J,358.3,11566,0)
 ;;=E22.2^^46^559^28
 ;;^UTILITY(U,$J,358.3,11566,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11566,1,3,0)
 ;;=3^SIADH
 ;;^UTILITY(U,$J,358.3,11566,1,4,0)
 ;;=4^E22.2
 ;;^UTILITY(U,$J,358.3,11566,2)
 ;;=^5002718
 ;;^UTILITY(U,$J,358.3,11567,0)
 ;;=E87.79^^46^559^10
 ;;^UTILITY(U,$J,358.3,11567,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11567,1,3,0)
 ;;=3^Fluid Overload,Other
 ;;^UTILITY(U,$J,358.3,11567,1,4,0)
 ;;=4^E87.79
 ;;^UTILITY(U,$J,358.3,11567,2)
 ;;=^5003025
 ;;^UTILITY(U,$J,358.3,11568,0)
 ;;=E21.0^^46^559^27
 ;;^UTILITY(U,$J,358.3,11568,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11568,1,3,0)
 ;;=3^Primary Hyperparathyroidism
 ;;^UTILITY(U,$J,358.3,11568,1,4,0)
 ;;=4^E21.0
 ;;^UTILITY(U,$J,358.3,11568,2)
 ;;=^331439
 ;;^UTILITY(U,$J,358.3,11569,0)
 ;;=E87.71^^46^559^30
 ;;^UTILITY(U,$J,358.3,11569,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11569,1,3,0)
 ;;=3^Transfusion Associated Circulatory Overload
 ;;^UTILITY(U,$J,358.3,11569,1,4,0)
 ;;=4^E87.71
 ;;^UTILITY(U,$J,358.3,11569,2)
 ;;=^5003024
 ;;^UTILITY(U,$J,358.3,11570,0)
 ;;=D63.1^^46^560^1
 ;;^UTILITY(U,$J,358.3,11570,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11570,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,11570,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,11570,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,11571,0)
 ;;=I12.0^^46^560^7
 ;;^UTILITY(U,$J,358.3,11571,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11571,1,3,0)
 ;;=3^HTN w/ CKD w/ Stage 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,11571,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,11571,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,11572,0)
 ;;=I95.1^^46^560^11
 ;;^UTILITY(U,$J,358.3,11572,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11572,1,3,0)
 ;;=3^Hypotension,Orthostatic
 ;;^UTILITY(U,$J,358.3,11572,1,4,0)
 ;;=4^I95.1
 ;;^UTILITY(U,$J,358.3,11572,2)
 ;;=^60741
 ;;^UTILITY(U,$J,358.3,11573,0)
 ;;=I95.89^^46^560^12
 ;;^UTILITY(U,$J,358.3,11573,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11573,1,3,0)
 ;;=3^Hypotension,Other
 ;;^UTILITY(U,$J,358.3,11573,1,4,0)
 ;;=4^I95.89
 ;;^UTILITY(U,$J,358.3,11573,2)
 ;;=^5008079
 ;;^UTILITY(U,$J,358.3,11574,0)
 ;;=N17.9^^46^560^13
 ;;^UTILITY(U,$J,358.3,11574,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11574,1,3,0)
 ;;=3^Kidney Failure,Acute,Unspec
 ;;^UTILITY(U,$J,358.3,11574,1,4,0)
 ;;=4^N17.9
 ;;^UTILITY(U,$J,358.3,11574,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,11575,0)
 ;;=N18.5^^46^560^3
 ;;^UTILITY(U,$J,358.3,11575,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11575,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 5
 ;;^UTILITY(U,$J,358.3,11575,1,4,0)
 ;;=4^N18.5
 ;;^UTILITY(U,$J,358.3,11575,2)
 ;;=^5015606
 ;;^UTILITY(U,$J,358.3,11576,0)
 ;;=N18.9^^46^560^4
 ;;^UTILITY(U,$J,358.3,11576,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11576,1,3,0)
 ;;=3^Chronic Kidney Disease,Unspec
 ;;^UTILITY(U,$J,358.3,11576,1,4,0)
 ;;=4^N18.9
 ;;^UTILITY(U,$J,358.3,11576,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,11577,0)
 ;;=N39.0^^46^560^15
 ;;^UTILITY(U,$J,358.3,11577,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11577,1,3,0)
 ;;=3^Urinary Tract Infection,Unspec Site
 ;;^UTILITY(U,$J,358.3,11577,1,4,0)
 ;;=4^N39.0
